The Board has never held many shares and the ones they held were the result of options exercised with ultra low strike prices - and they were generally sold on any share price spikes.
This demonstrates in spades just how little confidence any of these leaches has in the technology.
I would not agree that after all the years of research and money spent that BNC 210 is the wonder drug that it has been promoted as.
Nearly all of the trials were "soft" and the end points were mot designed to show efficacy but rather safety.
They may as well have been giving patients sugar pills because they too are safe and have no toxic side effects.
Demonstration of efficacy in psychometric drugs is difficult and extremely subjective.
The fact the the last trial failed with all the elements designed to test actual efficacy is the reason the Board decided it was a fail.
After the event they trawl through the entrails of the results looking for a hint that some aspect of the trial was not negative.
Aha!!! said Errol De Sousa - I can get overpaid as exec Chair while we stringing out another flaky trial for a specific condition that the wonder drug BNC 210 showed a modicum of effectiveness - yahoooo!
All aboard the Bionomics gravy train!!! Toot toot!!!!
As for overpayment of the Board - what more can I say.........you have nailed it.
I'd sack them all and start again.
BNO Price at posting:
14.5¢ Sentiment: Sell Disclosure: Not Held
